Select text to enable text to speech.

News

Image recruitment

08 May 2025

Join our Patients Working Group!

Are you living with a rare eye disease? Or are you a caretaker of someone who is? Join the Patients Working Group of the international research project Restore Vision! [Available in EN, IT, ES, FR, SE, DE]

Read more

Screenshot 2025-05-08 094722

08 May 2025

New study: mineralocorticoid receptor antagonism improves corneal integrity in a rat model of limbal stem cell deficiency

In this new study, our team at INSERM, explored whether mineralocorticoid receptor antagonists (MRAs)—commonly used for heart and kidney conditions—could aid corneal repair in limbal stem cell deficiency (LSCD), a rare and difficult-to-treat eye disease.

Read more

Screenshot 2025-05-01 155049

01 May 2025

New study: the role of Mesenchymal Stromal Cells and Apoptotic Bodies in immune regulation

Research has shown that MSC-derived ApoBDs can help regulate the immune system, however they have not been studied as much as smaller extracellular vesicles. To fill in the gap, our team at Galway conducted a study to explore the therapeutic potential of large and small ApoBDs.

Read more

layabstract 2

06 February 2025

Healing the cornea: the therapeutic potential of Mesenchymal Stromal Cells and their Extracellular Vesicles

In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.

Read more

inserm1

30 January 2025

New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.

Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.

Read more

LinkedIn Post

17 January 2025

Restore Vision’s first review meeting

On January, 16 the RESTORE VISION team held its first review meeting to assess project progress and discuss plans for the upcoming year.

Read more

Partecipa al nostro studio

11 December 2024

Partecipa al nostro studio presso l’Ospedale San Raffaele di Milano!

Aiutaci a far progredire la ricerca sulle malattie oculari rare!

Read more

Living with a Rare Eye Disease (1080 x 720 px) (1)

11 December 2024

Participate in our study in Milan, Italy!

Join our study in Milan, Italy and help us advance research on rare eye conditions!

Read more

IMG_5648

07 November 2024

Restore Vision at EVER 2024

Read more about Restore Vision Special Interest Session at EVER 2024 Congress

Read more

DOG 2024 Group Cologne

20 October 2024

Restore Vision team participates in DOG 2024 Congress

Last October 10, the Restore Vision team participated in the Deutsche Ophthalmologische Gesellschaft – DOG 2024.

Read more

RESTORE VISION

06 June 2024

Restore Vision 2nd consortium meeting

One year after the project kicked-off, our team met again in-person in Stockholm!

Read more

Picture6

05 June 2024

Restore Vision partners jointly host the 7th European Anirida Conference

Restore Vision partners participated in 7th European Aniridia Conference.

Read more

Wei Zhang

12 May 2024

Antisense eye drops only or combined with fine needle diathermy could be used to regress corneal neovascularization in mice – study by UKK

At the recent ARVO meeting, Wei Zhang presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice

Read more

Karina

12 May 2024

Genetic research shows promise for developing a treatment for the rare eye disease Aniridia – Study by UKK

At the recent ARVO meeting, Karina Hadriaan presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice

Read more

Picture poster

12 May 2024

Effectiveness of a new eyedrop in healing wounds on the cornea in rats – Study by INSERM

At the recent ARVO meeting, Daniela Braz presented the latest findings from INSERM on the development of a new eye drop to treat cornea wounds in mice.

Read more

1

12 May 2024

Exploring the use of spironolactone to treat diseases of the cornea – Study by INSERM

At the recent ARVO meeting, Raquel Gregorio presented the latest findings from INSERM on the use of spironolactone for treating corneal diseases.

Read more

3

11 May 2024

A novel combination treatment offers promise for corneal vessel regression and longer graft survival – Study by UKK

At the recent ARVO meeting, Meert Mestanoglu presented UKK’s ongoing research on a novel combination treatment for corneal vessel regression.

Read more

image

10 May 2024

Restore Vision partner KOL hosts Olisens symposium at SFO Congress

Restore Vision partner’s KOL host symposium on SFO 2024 and explored the use of Olisens on the treatment of Corneal Neovessels

Read more

image

09 May 2024

Restore Vision at ARVO Conference in Seattle

The Restore Vision Consortium had a significant presence at the ARVO 2024 “Vision for the Future” conference from 05th-09th May 2024 in Seattle, Washington to present our work on new therapies for rare ocular diseases.

Read more

RestoreVis

08 February 2024

A new eyedrop formulation of spirolactone helps corneal wound healing in rats

Learn more about Restore Vision’s preliminary results on a new eyedrop formulation.

Read more

Dr. Helen Busby (4)

21 December 2023

Restore Vision’s Ethics Advisor

Restore Vision is thrilled to welcome its new Ethics Advisor, Dr. Helen Busby, who will support the development and review of ethics applications for the project’s research involving human subjects.

Read more

Restore Vision Ethics Advisor

22 September 2023

The start of Restore Vision!

The Restore Vision project has officially started! A consortium of 10 European academic, clinical and enterprise partners led by University of Galway will research and test new treatments for rare eye diseases.

Read more

Interested in Restore vision?

Stay informed about our efforts to combat rare eye diseases and bring new hope to those affected by visual impairment by subscribing to our newsletter for updates on our latest treatments and research.